DUNBAR, GARY
Biography
Gary L. Dunbar received a B.A. in Philosophy and a B.S. in Biopsychology from
Publications & Presentations
†Fana, M., #Gallien, J., #Srinageshwar, B., Dunbar, G.L., Rossignol, J. (2020). PAMAM Dendrimer nanomolecules utilized as drug delivery systems for potential treatment of glioblastoma: A systematic review. International Journal of Nanomedicine 15:2789-2808. PubMedPMID: 32368055.
Maiti, P., #Plemmons, A., #Bowers, Z., Weaver, C., and Dunbar, G.L. (2020). Labeling and imaging of amyloid plaques in brain tissue using the natural polyphenol curcumin. J. Vis. Exp. (153): e60377; doi.org/10.3791/60377
#Srinageshwar, B., Petersen, R.B., Dunbar, G.L and Rossignol J, (2020). Prion‐like mechanisms in neurodegenerative disease: Implications for Huntington's disease therapy. Stem Cells Translational Medicine, 9:559–566. PubMed PMID:31997581.
Rossignol, J., Srinageshwar, B., and Dunbar, G.L. (2020). Current therapeutic strategies for glioblastoma. Brain Sciences 10(1): 15.
*Thompson, D., *Otero, P., Srinageshwar, B., Petersen, R.B., Dunbar, G.L., and Rossignol, J. (2020). Possible roles of epigenetics in stem cell therapy for Parkinson’s disease. Epigenomics 10.2217; doi:10.2217/epi-2019-0347
Srinageshwar, B. †Florendo, M., Clark, B., Johnson, K., Munro, N., Peruzzaro, S., Antcliff, A., Andrews, M., †Figacz, A., Swanson, D., Dunbar, G.L, Sharma, A., and Rossignol, J. (2020). A mixed-surface polyamidoamine dendrimer for in vitro and in vivo delivery of large plasmids. Pharmaceutics 12, 619, doi:10.3390/phamaceutics12070619.
Maiti, P., Manna, J., *Burch, Z.N., Flaherty, D.B., Larkin, J.D., and Dunbar, G.L. (2020). Ameliorative properties of boronic compounds in in vitro and in vivo models of Alzheimer’s disease. Int. J. Mol. Sci. 21, 6664; doi:10.3390/ijms21186664.
Gharaibeh, A., Maiti, P., Culver, R., Heilman, S., Srinageshwar, B., Story, D., Spelde, K., Paladugu, L., Munro, N., Muhn, N., Kolli, N., Rossignol, J., Dunbar, G.L. (2020). Solid lipid curcumin particles protect medium spiny neuronal morphology and reduce learning and memory deficits in the YAC128 mouse model of Huntington’s disease. Int. J. Mol. Sci 21 (24), 9542.
Maiti, P., #Bowers, Z.L., *Bourcier, A., *Morse, J., and Dunbar, G.L. (2021). Preservation of dendritic spine morphology and postsynaptic signaling markers after treatment with solid lipid curcumin particles in the 5xFAD mouse model of Alzheimer’s disease. Alzheimer’s Research & Therapy, 13: 37-59.
Paladugu, L., Gharaibeh, A., Kolli, N., Learman, C., Hall, T.C., Li, L., Rossignol, J., Maiti, P., and Dunbar, G.L. (2021). Liraglutide has anti-inflammatory and anti-amyloid properties in streptozotocin-induced and 5xFAD mouse models of Alzheimer’s disease. Int. J. Mol. Sci., 22(2), 860.
Banerjee, S., Mukherjee, B., Poddar, M.K., and Dunbar, G.L. (2021). Carnosine improves aging-induced cognitive impairment and brain regional neurodegeneration in relation to the neuropathological alterations in the secondary structure of amyloid beta (Aβ). Journal of Neurochemistry 158(3): 710-723.
Bose, R., Banerjee, S., and Dunbar, G.L. (2021). Modeling neurological disorders in 3D organoids using human-derived pluripotent stem cells. Frontiers in Cell and Developmental Biology, 9: 1-17.
Manna, JU., Dunbar, G.L., and Maiti, P. (2021). Curcugreen treatment prevented splenomegaly and other peripheral organ abnormalities in 3xTg and 5xFAD mouse models of Alzheimer’s disease. Antioxidants, 10(6): 899.
#Story, D., #Gallien, J., #Al-Gharibeh, A., Sandstrom, M., Rossignol, J., and Dunbar, G.L. (2021). Housing R6/2 mice with wild-type littermates increases lifespan. Journal of Huntington’s Disease. DOI 10.3233/JHD-210474.
Research Interests
Dr. Dunbar's teaching and research interests are in behavioral neuroscience. His recent research is focused on the using transplants of genetically altered stem cells, dietary supplements, and pharmacological treatments for cognitive/or motor deficits following brain damage, spinal cord injury, glioblastoma, and neurodegenerative diseases, such as Huntington's, Parkinson's and Alzheimer's diseases. His research has been supported by grants and contracts from the National Institute of Health, National Science Foundation, and several pharmaceutical companies and foundations.